BioTuesdays

Author - Leonard Zehr

Keryx Biopharmaceuticals Logo
Markets

Maxim downgrades Keryx Biopharmaceuticals to hold

Maxim Group downgraded Keryx Biopharmaceuticals (NASDAQ:KERX) to “hold” from “buy” and removed its price target for the stock, which was quoted at $5.16, down $2.20, or 30% in trading Monday afternoon. The move...

August 1, 2016
novadaq
Markets

Feltl upgrades Novadaq to strong buy

Feltl & Co. upgraded Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) to “strong buy” from “buy” after the company posted second quarter revenue ahead of expectations yesterday on the strength of its direct sales...

July 28, 2016
Executive Moves

Corey Davis joins HCW’s research team

Corey Davis has joined H.C. Wainwright in equity research as a managing director, covering specialty pharmaceuticals.Dr. Davis has 19 years of sell-side experience, covering specialty pharmaceutical companies, spending...

July 28, 2016
oramed
Developments

Oramed posts positive oral insulin data

Oramed Pharmaceuticals (NASDAQ:ORMP) reported additional data from the recently concluded Phase 2b trial of its oral insulin capsule ORMD-0801 in adults with Type 2 diabetes. The data indicate a statistically...

July 28, 2016
novadaq
Markets

Novadaq Q2 revenue climbs 34%

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) reported revenue of $20.1-million in the second quarter, an increase of 34% from $15.1-million a year ago. Total direct sales in the latest quarter increased by $4.4-million...

July 27, 2016
Anavex Life Sciences
Developments

Anavex reports Phase 2a efficacy data in AD

Anavex Life Sciences (NASDAQ:AVXL) announced efficacy data through 31 weeks from the ongoing ANAVEX 2-73 Phase 2a study in mild-to-moderate Alzheimer’s patients at the Alzheimer’s Association International Conference in...

July 27, 2016
NeoGenomics
Markets

BTIG downgrades NeoGenomics to neutral

BTIG Research downgraded NeoGenomics (NASDAQ:NEO) to “neutral” from “buy.” The stock closed at $9.05 on Tuesday. Analyst Dr. Sean Lavin writes that second quarter results were largely in-line. “The base business...

July 27, 2016
oramed
Executive Moves

Oramed names Dr. Roy Eldor as CMD

Oramed Pharmaceuticals (NASDAQ:ORMP) appointed Dr. Roy Eldor to the newly created post of chief medical director. “We are very pleased to welcome Dr. Eldor on board at this pivotal time for Oramed as we head towards a...

July 26, 2016